Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A European Medicines Agency (EMA) committee on Friday recommended adding heavy menstrual bleeding to the list of side effect of mRNA COVID-19 vaccines made by Moderna , as well as Pfizer and its partner BioNTech.

EU regulator recommends adding heavy periods to side effects of mRNA COVID shots

CAMBRIDGE, MA / ACCESSWIRE / October 27, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its first virtual ESG Day for analysts and investors at 9:00 a.m. ET on Thursday, November 10.

Moderna to Host First Environmental, Social and Governance (ESG) Day on November 10, 2022

CAMBRIDGE, MA / ACCESSWIRE / October 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it was ranked one of the top employers in the global biopharmaceutical industry by Science and Science Careers' 2022 Top Employers Survey for the eighth consecutive year. Moderna was ranked no.

Moderna Named a Top Employer by Science for Eighth Consecutive Year

Pfizer

There's still considerable near-term uncertainty for both of these vaccine makers.

Are Pfizer and Moderna Stocks Buys With a Potential COVID Surge Coming?

Moderna's shares have suffered amid concern about future vaccine revenue.

Could This News from Pfizer Equal Billions for Moderna?

Dollar General

Johnson & Johnson

Vertex Pharmaceuticals

Walmart

Recession-proof stocks must offer something that makes investors want to buy them even when the economy is tanking.

Which Stocks Are Most Likely to Thrive in a Recession? Here's What History Shows

The biotech could offset declining COVID-19 vaccine sales by raising prices.

Why Moderna Stock Rallied Today

BioNTech SE

Novavax

Stocks were set to open lower today, but the market seems to have found its groove. Everything from tech stocks to vaccine stocks are moving higher.

Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?

Pfizer and other pharma companies are under pressure to raise prices to meet revenue targets after government supplies of Covid vaccines runs out.

Pfizer's Covid Vaccine to Cost a Lot More. Why That's Good News for Moderna.

Moderna snagged an upgrade Friday on the likelihood it will hike the price of its Covid vaccine in 2023 — and MRNA stock jumped. The post Pfizer Quadruples Its Covid Shot Price — And Moderna Stock Surges appeared first on Investor's Business Daily.

Pfizer Quadruples Its Covid Shot Price — And Moderna Stock Surges

Moderna is preparing its business for a post-pandemic world.

Does This 1 Number Mean Trouble for Moderna?

AbbVie

Both companies are developing new drugs but that's where the similarities stop.

Which Stock Is More Likely to Double Your Money First: Moderna or AbbVie?

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.

Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab

Amazon

NIKE

Today's economic environment doesn't change these companies' long-term prospects.

3 Potentially Explosive Stocks You'll Want in Your Portfolio Before the Next Bull Market (and They're Dirt Cheap Now)

3 Things the Smartest Investors Know About This Beaten-Down Stock

Positive recommendation follows the recent approval of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, in September CAMBRIDGE, MA / ACCESSWIRE / October 19, 2022 / Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization for mRNA-1273.222 (Spikevax bivalent Original/Omicron BA.4-5) as a booster dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, who have previously received at least a primary vaccination course against COVID-19.

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union

Announcement follows CHMP's previous decision to issue a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include children 6 years of age and older Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults CAMBRIDGE, MA / ACCESSWIRE / October 19, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a variation to the conditional marketing authorization (CMA) to include a 25 µg two-dose series of Spikevax (mRNA-1273) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in children 6 months to 5 years. Following the CHMP's positive opinion, the European Commission will make an authorization decision on the use of Spikevax in children ages 6 months to 5 years.

EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union

The European Medical Agency on Wednesday recommended authorization of Moderna Inc's COVID-19 vaccine tailored towards targeting the Omicron sub-variants BA.4 and BA.5 for 12 and above ages.

EMA recommends Moderna's new Omicron-tailored vaccine

Traders who think Moderna stock will not reclaim the 50-day line could look at a bear call spread at 145-150. The post Moderna Stock Fails At Declining 50-Day Average; Check Out This Bearish Option Play appeared first on Investor's Business Daily.

Moderna Stock Fails At Declining 50-Day Average; Check Out This Bearish Option Play

Moderna Inc said on Wednesday its COVID-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months.

Moderna says Omicron booster response stays high through 3 months

Data indicate durable immune response from bivalent booster after three months of follow-up mRNA-1273.214 also demonstrated potent response to Omicron BA.2.75 CAMBRIDGE, MA / ACCESSWIRE / October 19, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited a superior neutralizing antibody response against Omicron BA.1 when compared to a 50 µg booster dose of mRNA-1273 in all participants regardless of prior infection.

90-Day Analysis Shows Moderna's Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster

The latest news about the coronavirus is encouraging, so the company's one commercialized product might not be such a popular item.

Why Moderna Stock Tripped and Fell on Tuesday

The company has been working on diversifying its pipeline.

Will This News Send Moderna's Stock Soaring?

It's important to understand Moderna's near-term challenges and its long-term opportunities.

News for Moderna Stock (MRNA)